Challenge Your Knowledge of New Treatments for Retinal Disease: DME (CE Monograph)

Activity Description and Purpose

Optometrists are at the forefront in the identification of patients with retinal disease and referral for management. Following this activity, clinicians will be able to identify opportunities for early referral of patients with diabetic retinopathy/diabetic macular edema and choose appropriate strategies for comanagement of patients with retinal disease. This activity will include a discussion on the efficacy and safety data of current treatments for diabetic retinopathy/diabetic macular edema. Finally, clinicians will be able to select appropriate strategies for counseling patients on managing treatment burden.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify opportunities for early referral of patients with diabetic macular edema
  • Choose appropriate strategies for comanagement of patients with retinal disease
  • Select appropriate strategies for counseling patients on managing treatment burden
  • Identify the efficacy and safety data relevant to clinical practice on dual mechanism of action of treatments for diabetic macular edema

You may also be interested in

Challenge Your Knowledge of New Treatments for Retinal Disease: nAMD (CE Monograph)
Following this educational activity, clinicians will be able to identify opportunities for early referral of patients with neovascular age-related macular degeneration and choose appropriate strategies for comanagement of patients with retinal disease.
Course summary
Available credit: 
  • 0.50 COPE
Course opens: 
05/17/2024
Course expires: 
05/31/2025

Faculty

Mohammad Rafieetary, OD, FAAO
Consultative Optometric Physician
Charles Retina Institute
Germantown, Tennessee

 

Katherine Talcott, MD
Cole Eye Institute
Cleveland Clinic
Cleveland, Ohio

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.

Faculty

Mohammad Rafieetary, OD, is a consultant for Apellis Pharmaceuticals, Astellas Pharma, Gyroscope*, Heidelberg Engineering GmbH, Iveric Bio, Inc, Notal Vision, Novartis Pharmaceuticals Corporation*, OcuTerra Therapeutics, Optos, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Apellis Pharmaceuticals, Astellas Pharma, Heidelberg Engineering GmbH, Iveric Bio, Inc, Notal Vision, Optos, and Regeneron Pharmaceuticals, Inc*.

Katherine Talcott, MD, is an advisory board member of Alimera Sciences, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, and Genentech, Inc; is on the speakers bureau for Astellas Pharma, Genentech, Inc, and Iveric Bio, Inc; and is a contracted researcher for Regeneron Pharmaceuticals, Inc, Regenxbio Inc, and Zeiss.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Cheryl Guttman Krader has individual stocks in AbbVie Inc and Johnson & Johnson Vision Care, Inc.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

 COPE approved for 0.5 CE credit for optometrists.
COPE Course ID: 91433-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease

Administrator:

This activity, COPE Activity Number 128468, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Genentech, Inc, for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Genentech, Inc.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 305b

Available Credit

  • 0.50 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.